WebDoctor Encyclopedia

Endocrine

Poorly differentiated thyroid carcinoma

Poorly differentiated thyroid carcinoma is an uncommon thyroid cancer that behaves between the slow-growing papillary type and anaplastic cancer. It often forms a large neck lump, may take up little iodine and is treated with surgery, radioiodine and targeted drugs.

Medically reviewed Last reviewed October 19, 2026

What is poorly differentiated thyroid carcinoma?

Poorly differentiated thyroid carcinoma (PDTC) is an uncommon thyroid cancer that sits between the common, slow-growing thyroid cancers and the very aggressive anaplastic thyroid cancer. It accounts for only a few per cent of thyroid cancers, but it causes a large share of thyroid cancer deaths.

Like papillary and follicular thyroid cancers, PDTC grows from the follicular cells of the thyroid, the cells that make thyroid hormone. “Poorly differentiated” means the cancer cells have lost much of their normal structure and function. They grow in solid sheets, divide faster and are less able to take up iodine.

PDTC may arise on its own or develop within a long-standing papillary or follicular cancer. In the 2022 World Health Organization classification, it is grouped with differentiated high-grade thyroid carcinoma as one of the high-grade follicular cell-derived thyroid cancers.

It usually affects adults over 50 and often presents as a large thyroid lump, sometimes with spread to the lungs or bones. Treatment combines surgery, radioactive iodine when the tumour still takes it up, radiotherapy and, for advanced disease, targeted tablets (Tong et al., 2022).

1. Key facts at a glance

Feature Details
Type of cancer High-grade thyroid cancer from follicular cells
How common Uncommon; a few per cent of thyroid cancers, varying between countries
Typical age Usually 50-70
Sex More common in women, but the gap is smaller than for papillary cancer
Typical presentation Large, firm thyroid lump; spread beyond the thyroid is common
Common sites of spread Neck lymph nodes, lungs, bone
Key gene changes RAS, TERT promoter, BRAF, TP53
Main treatment Total thyroidectomy, radioactive iodine if taken up, radiotherapy, targeted drugs
Outlook About 74% alive and 49% disease-free at 5 years in a pooled analysis

2. Where PDTC fits among thyroid cancers

Cancer Growth speed Iodine uptake Typical outlook
Papillary thyroid cancer Slow Usually good Excellent
Follicular thyroid cancer Slow Usually good Very good
Poorly differentiated thyroid carcinoma Moderate to fast Often reduced Intermediate
Differentiated high-grade thyroid carcinoma Moderate to fast Often reduced Intermediate
Anaplastic thyroid cancer Very fast None Poor

3. Causes and risk factors

The exact cause of PDTC is not known. Risk factors are similar to those for thyroid cancer in general.

Risk factor Notes
Older age Most patients are over 50
Radiation exposure in childhood A known cause of thyroid cancer
Long-standing goitre or iodine deficiency PDTC appears more common in iodine-deficient regions
Pre-existing well-differentiated cancer PDTC can develop within papillary or follicular cancer

Gene changes

Gene change Approximate frequency Notes
RAS mutations Common Typical of follicular-pattern tumours
TERT promoter mutations Common Linked with aggressive behaviour
BRAF V600E Less common than in papillary cancer A drug target when present
TP53 and other changes Some tumours Suggest progression towards anaplastic cancer
RET, NTRK or ALK fusions Rare Treatable with specific drugs

These changes develop in the tumour cells. PDTC is not usually inherited (Xu and Ghossein, 2020).

4. How does it look

In the neck

Feature Description
Lump A firm, often large thyroid nodule, usually over 3-4 cm
Growth May enlarge over weeks to months
Fixation Can feel fixed to surrounding tissues
Lymph nodes Swollen neck glands in some people

On scans

Scan Typical findings
Ultrasound A solid, dark (hypoechoic) nodule, sometimes with irregular edges
CT or MRI Shows the size of the tumour, spread outside the thyroid and involvement of the windpipe or gullet
Radioactive iodine scan Often shows reduced or patchy uptake
FDG PET-CT Often bright, reflecting high activity; useful when iodine scans are negative

Under the microscope

Pathologists usually use the Turin criteria to diagnose PDTC (Asioli et al., 2010):

Criterion Description
Growth pattern Solid, trabecular or insular (nest-like) growth
Nuclei Lack the typical features of papillary cancer
Plus at least one of Convoluted nuclei, 3 or more mitoses per 10 high-power fields, or tumour necrosis
Additional feature Notes
Thyroglobulin stain Often weaker or patchy
TTF-1 and PAX8 Positive, confirming thyroid origin
Ki-67 Higher than in well-differentiated cancers

5. Symptoms

Some people have no symptoms apart from a lump. Others have symptoms caused by pressure on nearby structures.

Common symptoms

  • A lump in the front of the neck that may grow over weeks or months
  • Hoarseness or a change in voice
  • Difficulty swallowing
  • Breathlessness or noisy breathing, from pressure on the windpipe
  • Swollen glands in the neck
  • A feeling of pressure or tightness in the neck

Symptoms of spread

Site Possible symptoms
Lungs Cough, breathlessness, chest pain, coughing blood
Bone Bone pain, fracture, back pain
Brain Headache, weakness, seizures (rare)

Thyroid function

Most people with PDTC have normal thyroid hormone levels, so they do not notice symptoms of an overactive or underactive thyroid.

When to seek medical advice

See a doctor about a lump in the neck, especially if it is growing, hard, or linked with hoarseness, swallowing problems or breathlessness. Seek urgent care for difficulty breathing or noisy breathing.

6. Diagnosis

Test Purpose
Neck examination Assesses the lump and lymph nodes
Thyroid ultrasound Shows the nodule’s features and guides biopsy
Fine needle aspiration (FNA) or core biopsy Takes cells for diagnosis; PDTC is often only fully confirmed after surgery
Blood tests Thyroid function, thyroglobulin and calcitonin
Laryngoscopy Checks the movement of the vocal cords
CT of the neck and chest Assesses local extent and lung spread
FDG PET-CT Detects spread, especially when iodine uptake is low
Molecular testing Identifies BRAF, RET, NTRK and other targetable changes

Staging

Thyroid cancers of follicular cell origin are staged with the TNM system, and age at diagnosis is part of the staging. People under 55 are classed as stage I unless there is distant spread, while older people are staged according to tumour size, spread outside the thyroid and lymph node involvement.

Factor Why it matters
Tumour size Larger tumours behave worse
Extrathyroidal extension Growth into the neck muscles, windpipe or nerves is a strong warning sign
Lymph node spread Raises the risk of recurrence in the neck
Distant spread Most often to the lungs and bones
Age Outcomes are less favourable in older patients

7. Treatment

Treatment is planned by a thyroid cancer multidisciplinary team, including endocrine surgeons, endocrinologists, nuclear medicine doctors and oncologists.

Surgery

Operation Notes
Total thyroidectomy Removal of the whole thyroid; the standard operation
Central neck dissection Removal of lymph nodes next to the thyroid
Lateral neck dissection When lymph nodes at the side of the neck are involved
Extended surgery When the tumour invades the windpipe, gullet or larynx

Complete removal of all visible cancer is the most important factor for a good outcome.

Radioactive iodine (RAI)

After thyroidectomy, radioactive iodine is offered if the tumour still takes up iodine. Many PDTCs take up iodine weakly or not at all, so RAI helps some patients but not others. Uptake is checked on post-treatment scans.

Radioactive iodine treatment step by step

Step What happens
1. Preparation A low-iodine diet for 1-2 weeks and injections of recombinant TSH, or a short break from thyroid tablets
2. Treatment A capsule or drink of radioactive iodine, usually given during a short hospital stay
3. Isolation A few days in a single room, then limited close contact at home for a short period
4. Scan A whole-body scan a few days later shows where the iodine has gone
5. Review Blood tests and scans months later check whether the treatment worked

What does iodine-refractory mean?

Normal thyroid cells, and many well-differentiated thyroid cancers, absorb iodine from the blood. This is why radioactive iodine can destroy them from the inside. Poorly differentiated cancers often lose this ability.

When a tumour does not take up iodine, or keeps growing despite it, doctors call it iodine-refractory. At that point, further iodine treatment is unlikely to help, and targeted drugs, radiotherapy or surgery become the main options.

External beam radiotherapy

Radiotherapy to the neck may be recommended when the cancer has grown outside the thyroid, when margins are positive, or when there is residual disease that does not take up iodine. It is also used to relieve pain from bone metastases.

Targeted drugs for advanced disease

Drug Target Notes
Lenvatinib Multiple kinases (VEGFR and others) Standard first option for progressive iodine-refractory disease
Sorafenib Multiple kinases An alternative first-line option
Cabozantinib Multiple kinases After earlier treatment
Dabrafenib plus trametinib BRAF V600E For BRAF-mutated tumours
Selpercatinib or pralsetinib RET fusions For RET fusion-positive tumours
Larotrectinib or entrectinib NTRK fusions For NTRK fusion-positive tumours

Side effects

Treatment Possible side effects
Thyroidectomy Hoarse voice, low calcium, need for lifelong thyroid hormone tablets
Radioactive iodine Dry mouth, taste changes, swelling of salivary glands
Radiotherapy Sore throat, difficulty swallowing, skin changes, tiredness
Kinase inhibitors High blood pressure, diarrhoea, tiredness, weight loss, hand-foot skin reaction, protein in the urine

8. Outlook (prognosis)

Measure Pooled figure
5-year overall survival About 74%
5-year disease-free survival About 49%
Strongest risk factor Spread of the cancer outside the thyroid (extrathyroidal extension)

These figures come from a 2024 analysis of 20 studies and almost 1,300 patients treated with surgery (Kim et al., 2024). The outlook is best when the cancer is confined to the thyroid and completely removed. It is worse in older patients, with large tumours, distant spread at diagnosis or tumours that do not take up iodine.

9. Follow-up

Follow-up Purpose
Thyroglobulin blood tests A rising level may suggest recurrence, although PDTC may make less thyroglobulin
Neck ultrasound Detects recurrence in the neck
CT chest and PET-CT For high-risk patients or rising tumour markers
Thyroid hormone dose checks Keeps TSH at the target set by the team
Calcium and voice checks After surgery

10. Living with poorly differentiated thyroid carcinoma

  • Take levothyroxine every day, ideally on an empty stomach at the same time each day
  • Keep regular blood tests to check hormone levels and tumour markers
  • Follow radiation safety advice after radioactive iodine treatment
  • Manage side effects of targeted drugs with your team, including blood pressure checks
  • Report new symptoms such as cough, bone pain or a new neck lump
  • Carry a list of your medicines, including your levothyroxine dose, to every appointment
  • Look after your voice with speech therapy if it has changed after surgery
  • Seek support from thyroid cancer charities and patient groups

11. Frequently asked questions

Question Answer
Is PDTC the same as anaplastic thyroid cancer? No. It is less aggressive, but more serious than papillary or follicular cancer
Will radioactive iodine work? It helps if the tumour takes up iodine; many PDTCs take up less than usual
Do I need tablets for life? Yes, thyroid hormone replacement is lifelong after total thyroidectomy
Is it inherited? Usually not
Can it be cured? Yes, especially when found early and completely removed
Will I need a feeding tube or tracheostomy? Rarely; only when the cancer has invaded the gullet or windpipe extensively
Can I have children after treatment? Usually yes, but pregnancy is generally delayed for 6-12 months after radioactive iodine
What if it spreads? Targeted tablets can control the disease, often for long periods

12. Questions to ask your care team

  • Was the cancer completely removed?
  • Has it spread outside the thyroid or to lymph nodes?
  • Will radioactive iodine be useful for me?
  • Do I need external radiotherapy?
  • Has the tumour been tested for BRAF, RET or NTRK changes?
  • How often will I have scans and blood tests?

Resources

  1. Asioli, S. et al. (2010) ‘Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression’, Modern Pathology, 23(9), pp. 1269-1278.
  2. Kim, J.Y. et al. (2024) ‘Prognosis of poorly differentiated thyroid carcinoma: a systematic review and meta-analysis’, Endocrinology and Metabolism, 39(4), pp. 590-602.
  3. Tong, J. et al. (2022) ‘Poorly differentiated thyroid carcinoma: a clinician’s perspective’, European Thyroid Journal, 11(2), e220021.
  4. Xu, B. and Ghossein, R. (2020) ‘Poorly differentiated thyroid carcinoma’, Seminars in Diagnostic Pathology, 37(5), pp. 243-247.
  5. National Cancer Institute (2026) Thyroid Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.